Skip to content

US · IMRX · BIOTECHNOLOGY

Immuneering Corporation (IMRX) intrinsic value and stock valuation

$3.38as of 2026-11-21 · Mkt cap 163.72M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Immuneering Corporation DCF and intrinsic value

InvestorsCraft values IMRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IMRX’s statements →

Immuneering Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 immuneering.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-56.02M
20192025
Free cash flow
-$-45.49M
20192025
Total equity
$218.5M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$320K$2.08M
Operating income-$-59.38M-$-64.07M-$-58.41M-$-51.74M-$-33.89M
Net income-$-56.02M-$-61.04M-$-53.47M-$-50.51M-$-33.54M
EPSd-$-1.27M-$-2.04M-$-1.88M-$-1.91M-$-1.27M
Operating cash flow-$-45.34M-$-55M-$-48.97M-$-44.1M-$-30.85M
Capital expenditure-$-140K-$-80K-$-340K-$-740K-$-60K
Free cash flow-$-45.49M-$-55.08M-$-49.31M-$-44.84M-$-30.91M
Total assets$232M$52.7M$102.6M$122.4M$166.7M
Total debt$3.82M$4.16M$4.46M$4.84M$5.36M
Net debt-$-124.82M-$-31.98M-$-54.94M-$-67.8M-$-69.52M
Total equity$218.5M$41.4M$90.6M$109.9M$156M
Cash and short-term investments$172.8M$36.1M$85.7M$105.5M$149.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$320K$2.08M
Cost of revenue$700K$0.00$0.00$160K$1.15M
Gross profit-$-700K$0.00$0.00$160K$930K
Research and development expenses$42.1M$48M$41.6M$36.3M$26.5M
Selling, general and administrative expenses$17.3M$16.1M$16.8M$15.6M$8.27M
Other expenses-$-670K$30K$30K$30K$0.00
Operating expenses$58.7M$64.1M$58.4M$51.9M$34.8M
Cost and expenses$59.4M$64.1M$58.4M$52.1M$36M
Interest income$3.04M$2.59M$3.61M$1.01M$170K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$700K$390K$350K$280K$160K
Ebitda-$-55.33M-$-63.69M-$-58.06M-$-51.47M-$-33.68M
Operating income-$-59.38M-$-64.07M-$-58.41M-$-51.74M-$-33.89M
Total other income/expenses, net$3.35M$3.03M$4.94M$1.23M$40K
Income before tax-$-56.02M-$-61.04M-$-53.47M-$-50.51M-$-33.84M
Income tax expense$0.00$0.00$0.00$0.00-$-310K
Net income-$-56.02M-$-61.04M-$-53.47M-$-50.51M-$-33.54M
Weighted average shares outstanding$44M$30M$28.4M$26.4M$26.3M
Weighted average diluted shares outstanding$44M$30M$28.4M$26.4M$26.3M
Balance sheet
20252024202320222021
Cash and short-term investments$172.8M$36.1M$85.7M$105.5M$149.2M
Net receivables$0.00$0.00$0.00$10K$250K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$176.3M$39.6M$89.1M$108.8M$152.3M
Property, plant and equipment, net$4.26M$4.79M$5.4M$5.78M$6.13M
Goodwill and intangible assets$7.01M$7.04M$7.07M$7.1M$7.14M
Long-term investments$0.00$0.00$0.00$0.00$1M
Total non-current assets$55.7M$13.1M$13.5M$13.6M$14.4M
Total assets$232M$52.7M$102.6M$122.4M$166.7M
Accounts payable$1.54M$1.96M$2.11M$3.15M$1.39M
Short-term debt$400K$340K$300K$380K$270K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$10.1M$7.5M$7.85M$8.05M$5.63M
Long-term debt$3.43M$3.82M$4.16M$4.46M$5.09M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3.43M$3.82M$4.16M$4.46M$5.09M
Capital lease obligations$3.82M$4.16M$4.46M$4.84M$5.36M
Total liabilities$13.5M$11.3M$12M$12.5M$10.7M
Common stock$60K$30K$30K$30K$30K
Retained earnings-$-280.32M-$-224.3M-$-163.26M-$-109.79M-$-59.27M
Accumulated other comprehensive income (loss)$80K$0.00-$0.00-$-30K-$-50K
Total equity$218.5M$41.4M$90.6M$109.9M$156M
Total investments$44.2M$0.00$26.3M$32.9M$75.3M
Total debt$3.82M$4.16M$4.46M$4.84M$5.36M
Net debt-$-124.82M-$-31.98M-$-54.94M-$-67.8M-$-69.52M
Cash flow statement
20252024202320222021
Net income-$-56.02M-$-61.04M-$-53.47M-$-50.51M-$-33.54M
Depreciation and amortization$700K$390K$350K$800K$160K
Stock-based compensation$0.00$6.5M$5.73M$0.00$1.8M
Change in working capital$3.82M-$-930K-$-970K$1.72M$900K
Accounts receivable$0.00$0.00$10K$230K$280K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-400K-$-110K-$-1.11M$1.76M-$-130K
Net cash provided by operating activities-$-45.34M-$-55M-$-48.97M-$-44.1M-$-30.85M
Investments in property, plant and equipment-$-140K-$-80K-$-340K-$-740K-$-60K
Acquisitions, net$0.00$0.00$0.00$0.00$70K
Net cash used for investing activities-$-88.74M$26.4M$7.3M$41.8M-$-75.62M
Common stock issued$226.6M$4.24M$28.2M$20K$120.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$226.6M$5.3M$28.4M$20K$144.3M
Net change in cash$92.5M-$-23.26M-$-13.23M-$-2.25M$37.8M
Cash at end of period$128.7M$36.1M$59.4M$72.6M$74.9M
Operating cash flow-$-45.34M-$-55M-$-48.97M-$-44.1M-$-30.85M
Capital expenditure-$-140K-$-80K-$-340K-$-740K-$-60K
Free cash flow-$-45.49M-$-55.08M-$-49.31M-$-44.84M-$-30.91M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Immuneering Corporation

        Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.

        CEO
        Benjamin J. Zeskind
        Employees
        37
        Beta
        0.37

        Explore

        Frequently asked questions

        What is the intrinsic value of Immuneering Corporation (IMRX)?

        InvestorsCraft does not currently publish an intrinsic value for IMRX. How the IC value is calculated.

        Is IMRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for IMRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.